JP2004512281A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004512281A5 JP2004512281A5 JP2002532443A JP2002532443A JP2004512281A5 JP 2004512281 A5 JP2004512281 A5 JP 2004512281A5 JP 2002532443 A JP2002532443 A JP 2002532443A JP 2002532443 A JP2002532443 A JP 2002532443A JP 2004512281 A5 JP2004512281 A5 JP 2004512281A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- pharmaceutically acceptable
- substituted
- acceptable salt
- benzo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 description 22
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- 150000001875 compounds Chemical group 0.000 description 9
- 150000003839 salts Chemical class 0.000 description 9
- 125000000547 substituted alkyl group Chemical group 0.000 description 8
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- 125000005605 benzo group Chemical group 0.000 description 5
- 150000002431 hydrogen Chemical class 0.000 description 5
- 229910052736 halogen Inorganic materials 0.000 description 4
- 150000002367 halogens Chemical class 0.000 description 4
- 125000000623 heterocyclic group Chemical group 0.000 description 4
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 125000004093 cyano group Chemical group *C#N 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 125000001072 heteroaryl group Chemical group 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 125000004414 alkyl thio group Chemical group 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- ODFIBXFJCDPCHA-UHFFFAOYSA-N 1-methyl-4-methylaminobenzo(g)imidazo(4,5-c)quinoline Chemical compound C1=CC=C2C=C(C3=C(C(NC)=N4)N=CN3C)C4=CC2=C1 ODFIBXFJCDPCHA-UHFFFAOYSA-N 0.000 description 1
- WTPHYSIDMNOBOL-UHFFFAOYSA-N 12-thia-14,17-diazatetracyclo[8.7.0.03,8.011,15]heptadeca-1,3,5,7,9,11(15),13,16-octaene Chemical compound C1=CC=CC2=CC3=C(SC=N4)C4=CN=C3C=C21 WTPHYSIDMNOBOL-UHFFFAOYSA-N 0.000 description 1
- ITIRVXDSMXFTPW-UHFFFAOYSA-N 1H-imidazo[4,5-c]quinoline Chemical compound C1=CC=CC2=C(NC=N3)C3=CN=C21 ITIRVXDSMXFTPW-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- HYIUUGVUYIIERY-UHFFFAOYSA-N CNC1=NC2=CC3=CC=CC=C3C=C2C2=C1N=C[S+]2C Chemical compound CNC1=NC2=CC3=CC=CC=C3C=C2C2=C1N=C[S+]2C HYIUUGVUYIIERY-UHFFFAOYSA-N 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- UMGOIQFASVFXBU-UHFFFAOYSA-N chembl230184 Chemical compound C1=CC=C2C=C(N3C(C)=CN=C3C(NCCO)=N3)C3=CC2=C1 UMGOIQFASVFXBU-UHFFFAOYSA-N 0.000 description 1
- KFIFSKNSIUVOCG-UHFFFAOYSA-N chembl230185 Chemical compound N=1C2=CC3=CC=CC=C3C=C2N2C(C)=CN=C2C=1NCCN1CCCCC1 KFIFSKNSIUVOCG-UHFFFAOYSA-N 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22330400P | 2000-10-03 | 2000-10-03 | |
| US60/223,304 | 2000-10-03 | ||
| PCT/US2001/042387 WO2002028860A2 (en) | 2000-10-03 | 2001-09-27 | Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004512281A JP2004512281A (ja) | 2004-04-22 |
| JP2004512281A5 true JP2004512281A5 (enExample) | 2008-11-06 |
| JP5021148B2 JP5021148B2 (ja) | 2012-09-05 |
Family
ID=22835931
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002532443A Expired - Fee Related JP5021148B2 (ja) | 2000-10-03 | 2001-09-27 | 抗炎症薬として有用なアミノ置換４環化合物および該化合物を含有する医薬組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US6960585B2 (enExample) |
| EP (1) | EP1325009B1 (enExample) |
| JP (1) | JP5021148B2 (enExample) |
| AT (1) | ATE319713T1 (enExample) |
| AU (2) | AU1182702A (enExample) |
| CA (1) | CA2424303A1 (enExample) |
| DE (1) | DE60117835T2 (enExample) |
| ES (1) | ES2260300T3 (enExample) |
| HU (1) | HUP0302925A3 (enExample) |
| WO (1) | WO2002028860A2 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3980602A (en) | 2000-10-26 | 2002-06-03 | Tularik Inc | Antiinflammation agents |
| EP1363993A4 (en) * | 2001-02-01 | 2008-11-12 | Bristol Myers Squibb Co | METHOD FOR THE TREATMENT OF INFLAMMATORY AND IMMUNE DISEASES USING I KAPPA B KINASE (IKK) |
| WO2003048152A2 (en) | 2001-12-05 | 2003-06-12 | Tularik Inc. | Inflammation modulators |
| JP2006512313A (ja) | 2002-10-31 | 2006-04-13 | アムジェン インコーポレイテッド | 抗炎症剤 |
| PE20060373A1 (es) | 2004-06-24 | 2006-04-29 | Smithkline Beecham Corp | Derivados 3-piperidinil-7-carboxamida-indazol como inhibidores de la actividad cinasa de ikk2 |
| TW200626142A (en) | 2004-09-21 | 2006-08-01 | Glaxo Group Ltd | Chemical compounds |
| US8063071B2 (en) | 2007-10-31 | 2011-11-22 | GlaxoSmithKline, LLC | Chemical compounds |
| WO2007005534A2 (en) | 2005-06-30 | 2007-01-11 | Smithkline Beecham Corporation | Chemical compounds |
| EP1928887B1 (en) | 2005-08-05 | 2014-12-17 | Senhwa Biosciences, Inc. | Methods of preparing quinolone analogs |
| US20090175852A1 (en) | 2006-06-06 | 2009-07-09 | Schering Corporation | Imidazopyrazines as protein kinase inhibitors |
| CN101553491B (zh) * | 2006-12-13 | 2013-05-29 | Aska制药株式会社 | 喹喔啉衍生物 |
| PE20081889A1 (es) | 2007-03-23 | 2009-03-05 | Smithkline Beecham Corp | Indol carboxamidas como inhibidores de ikk2 |
| AU2009298981B2 (en) | 2008-10-02 | 2012-09-27 | Asahi Kasei Pharma Corporation | 8-substituted isoquinoline derivative and use thereof |
| US8354539B2 (en) | 2009-03-10 | 2013-01-15 | Glaxo Group Limited | Indole derivatives as IKK2 inhibitors |
| CN102288753A (zh) * | 2011-05-10 | 2011-12-21 | 重庆市科学技术研究院 | 快速检测四环素、金霉素、土霉素与多西环素残留的四联胶体金免疫层析试纸条及其制备方法 |
| US9758518B2 (en) | 2015-03-04 | 2017-09-12 | Pimera, Inc. | Compositions, uses and methods for making them |
| KR102044648B1 (ko) * | 2014-05-09 | 2019-11-13 | 피메라, 아이엔씨. | 신규한 조성물, 용도 및 이를 제조하기 위한 방법 |
| US11912706B2 (en) | 2017-03-28 | 2024-02-27 | Pimera, Inc. | Crystal forms of a POL1 inhibitor |
| JOP20180094A1 (ar) | 2017-10-18 | 2019-04-18 | Hk Inno N Corp | مركب حلقي غير متجانس كمثبط بروتين كيناز |
| KR102195348B1 (ko) | 2018-11-15 | 2020-12-24 | 에이치케이이노엔 주식회사 | 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4236015A (en) | 1977-01-07 | 1980-11-25 | Westwood Pharmaceuticals, Inc. | 1-(2-Acylaminophenyl)imidazoles |
| US4160097A (en) | 1977-01-07 | 1979-07-03 | Westwind Pharmaceuticals, Inc. | 1-(2-Phenylureylene)imidazoles |
| US4225724A (en) * | 1977-01-07 | 1980-09-30 | Westwood Pharmaceuticals, Inc. | 1-(2-Phenylureylene)imidazoles |
| US5153196A (en) * | 1991-06-05 | 1992-10-06 | Eli Lilly And Company | Excitatory amino acid receptor antagonists and methods for the use thereof |
| US5196421A (en) | 1991-06-05 | 1993-03-23 | Eli Lilly And Company | Excitatory amino acid receptor antagonists in methods for the use thereof |
| US5182386A (en) | 1991-08-27 | 1993-01-26 | Neurogen Corporation | Certain imidazoquinoxalinones; a new class of gaba brain receptor ligands |
| US5266575A (en) | 1991-11-06 | 1993-11-30 | Minnesota Mining And Manufacturing Company | 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines |
| FR2696466B1 (fr) | 1992-10-02 | 1994-11-25 | Rhone Poulenc Rorer Sa | Dérivés de 5H,10H-imidazo[1,2-a]indeno[1,2-e]pyrazine-4-one, leur préparation et les médicaments les contenant. |
| IT1276167B1 (it) | 1995-11-24 | 1997-10-27 | Foscama Biomed Chim Farma | Imidazo(1,2-alfa)chinossalin-4-ammine attivi come antagonisti adenosinici,procedimento per la loro preparazione e loro composizioni |
| US6235740B1 (en) | 1997-08-25 | 2001-05-22 | Bristol-Myers Squibb Co. | Imidazoquinoxaline protein tyrosine kinase inhibitors |
| WO1999045009A1 (en) | 1998-03-04 | 1999-09-10 | Bristol-Myers Squibb Company | Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors |
| US6869956B2 (en) * | 2000-10-03 | 2005-03-22 | Bristol-Myers Squibb Company | Methods of treating inflammatory and immune diseases using inhibitors of IκB kinase (IKK) |
| EP1363993A4 (en) * | 2001-02-01 | 2008-11-12 | Bristol Myers Squibb Co | METHOD FOR THE TREATMENT OF INFLAMMATORY AND IMMUNE DISEASES USING I KAPPA B KINASE (IKK) |
-
2001
- 2001-09-27 ES ES01979911T patent/ES2260300T3/es not_active Expired - Lifetime
- 2001-09-27 WO PCT/US2001/042387 patent/WO2002028860A2/en not_active Ceased
- 2001-09-27 EP EP01979911A patent/EP1325009B1/en not_active Expired - Lifetime
- 2001-09-27 US US09/965,977 patent/US6960585B2/en not_active Expired - Lifetime
- 2001-09-27 HU HU0302925A patent/HUP0302925A3/hu unknown
- 2001-09-27 CA CA002424303A patent/CA2424303A1/en not_active Abandoned
- 2001-09-27 JP JP2002532443A patent/JP5021148B2/ja not_active Expired - Fee Related
- 2001-09-27 AU AU1182702A patent/AU1182702A/xx active Pending
- 2001-09-27 DE DE60117835T patent/DE60117835T2/de not_active Expired - Lifetime
- 2001-09-27 AT AT01979911T patent/ATE319713T1/de not_active IP Right Cessation
- 2001-09-27 AU AU2002211827A patent/AU2002211827B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004512281A5 (enExample) | ||
| JP2005535586A5 (enExample) | ||
| RU2018100142A (ru) | Гетероциклические соединения, эффективные для ингибирования киназы | |
| JP2014525432A5 (enExample) | ||
| WO2004058753A8 (en) | Thiadiazoles or oxadiazoles and their use as inhibitors of jak protein kinase | |
| JP2007517807A5 (enExample) | ||
| WO2006034341A3 (en) | Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase | |
| CY1110676T1 (el) | ΠΥΡΑΖΟΛΟ[3,4-b]ΠΥΡΙΔΙΝΙΚΕΣ ΕΝΩΣΕΙΣ, ΚΑΙ Η ΧΡΗΣΗ ΤΟΥΣ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΤΗΣ ΦΩΣΦΟΔΙΕΣΤΕΡΑΣΗΣ | |
| MX2007003329A (es) | Derivados heterociclicos y biciclicos y su uso como inhibidores de estearoil-coa-desaturasa (scd). | |
| WO2006101521A3 (en) | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors | |
| RU2004132844A (ru) | Производные бензамида, полехные в качестве ингибиторов деацетилазы гистонов | |
| MY127066A (en) | Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors. | |
| JP2006514691A5 (enExample) | ||
| CA2445333A1 (en) | Quinoline derivatives and quinazoline derivatives having azolyl group | |
| RU2000127751A (ru) | Противоопухолевое средство | |
| EP1465631A4 (en) | A2B RECEPTOR-BASED ANTAGONIST PYRIMIDINE COMPOUNDS, THEIR SYNTHESIS AND USE THEREOF | |
| JP2012528166A5 (enExample) | ||
| JP2015537001A5 (enExample) | ||
| WO2006034440A3 (en) | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors | |
| JP2005519932A5 (enExample) | ||
| JP2006507235A5 (enExample) | ||
| JP2005509622A5 (enExample) | ||
| JP2007501831A5 (enExample) | ||
| JP2012513390A5 (enExample) | ||
| JP2010501478A5 (enExample) |